MD967Z - Метод лечения хронического вирусного гепатита В с холестатическим синдромом у детей - Google Patents
Метод лечения хронического вирусного гепатита В с холестатическим синдромом у детей Download PDFInfo
- Publication number
- MD967Z MD967Z MDS20150032A MDS20150032A MD967Z MD 967 Z MD967 Z MD 967Z MD S20150032 A MDS20150032 A MD S20150032A MD S20150032 A MDS20150032 A MD S20150032A MD 967 Z MD967 Z MD 967Z
- Authority
- MD
- Moldova
- Prior art keywords
- treatment
- glucopyranosyl
- children
- hvb
- viral hepatitis
- Prior art date
Links
- 230000001684 chronic effect Effects 0.000 title claims abstract description 19
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 19
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 17
- 230000001587 cholestatic effect Effects 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 title claims description 12
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims abstract description 22
- 229960001661 ursodiol Drugs 0.000 claims abstract description 22
- 230000037396 body weight Effects 0.000 claims abstract description 7
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 21
- 238000012937 correction Methods 0.000 claims description 3
- 238000001784 detoxification Methods 0.000 claims description 3
- 230000002443 hepatoprotective effect Effects 0.000 claims description 3
- 230000004060 metabolic process Effects 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 229930185631 capsicoside Natural products 0.000 description 19
- 206010058874 Viraemia Diseases 0.000 description 17
- 206010008635 Cholestasis Diseases 0.000 description 10
- 231100000359 cholestasis Toxicity 0.000 description 10
- 230000007870 cholestasis Effects 0.000 description 10
- 230000000840 anti-viral effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000010606 normalization Methods 0.000 description 5
- 206010019842 Hepatomegaly Diseases 0.000 description 4
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 3
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 3
- 230000004596 appetite loss Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 235000021266 loss of appetite Nutrition 0.000 description 3
- 208000019017 loss of appetite Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- SEBFKMXJBCUCAI-WAABAYLZSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2s,3s)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-WAABAYLZSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 201000001352 cholecystitis Diseases 0.000 description 2
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 229960004245 silymarin Drugs 0.000 description 2
- 235000017700 silymarin Nutrition 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010048714 Gastroduodenitis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 201000003947 acalculous cholecystitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000007727 cost benefit analysis Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002091 elastography Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001787 epileptiform Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- LELAOEBVZLPXAZ-UHFFFAOYSA-N iberin Chemical compound CS(=O)CCCN=C=S LELAOEBVZLPXAZ-UHFFFAOYSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Steroid Compounds (AREA)
Abstract
Изобретение относится к медицине, в частности к детской гепатологии и инфекционным заболеваниям и может быть использовано для лечения хронического вирусного гепатита В с холестатическим синдромом у детей.Сущность изобретения заключается в том, что выполняют основное лечение, а одновременно вводят per os 5α-фуростан-3β,22,26-триол-3-[O-β-D-глукопиранозил(1→2)- β-D- глукопиранозил (1→4)- β-D- галактопиранозил]-26-O-β-D- глукопиранозид 100 мг, 2 раза в день, 3-O-[β-D- глукопиранозил (1→2)]-[ β-D- глукопиранозил (1→3)]-[ β-D- глукопиранозил (1→4)]- β-D-галактопиранозил[(25R)-5α- фуростан -2α, 3β, 22α, 26-тетраол]-26-O-β-D- глукопиранозид 50 мг и урсодезоксихолевую кислоту 15 мг/кг массы тела, один раз в день, в течение 24-х недель.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20150032A MD967Z (ru) | 2015-03-10 | 2015-03-10 | Метод лечения хронического вирусного гепатита В с холестатическим синдромом у детей |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20150032A MD967Z (ru) | 2015-03-10 | 2015-03-10 | Метод лечения хронического вирусного гепатита В с холестатическим синдромом у детей |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD967Y MD967Y (ru) | 2015-11-30 |
| MD967Z true MD967Z (ru) | 2016-06-30 |
Family
ID=54753231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20150032A MD967Z (ru) | 2015-03-10 | 2015-03-10 | Метод лечения хронического вирусного гепатита В с холестатическим синдромом у детей |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD967Z (ru) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD1875G2 (ru) * | 1999-11-01 | 2002-09-30 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Метод лечения острого вирусного гепатита В |
-
2015
- 2015-03-10 MD MDS20150032A patent/MD967Z/ru not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD1875G2 (ru) * | 1999-11-01 | 2002-09-30 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Метод лечения острого вирусного гепатита В |
Non-Patent Citations (2)
| Title |
|---|
| American Association for Study of Liver Deseases (AASLD). Guidelines for children, 2001 * |
| Lous-Jacques O., Olson A.D. Cost-Benefit Analysis of Interferon Therapyin Children with Chronic Active Hepatitis B. J. Ped. Gastr. Nutr. 1997, Nr. 24, p. 25-32 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD967Y (ru) | 2015-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shahidi et al. | Testosterone-induced remission in aplastic anemia of both acquired and congenital types: further observations in 24 cases | |
| JP6441313B2 (ja) | ドラベ症候群の処置における使用のためのフェンフルラミン | |
| Rigante et al. | The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever | |
| Mori et al. | Beneficial effects of fucoidan in patients with chronic hepatitis C virus infection | |
| Rigano et al. | Real-life experience with hydroxyurea in sickle cell disease: a multicenter study in a cohort of patients with heterogeneous descent | |
| McCracken Jr et al. | Cytosine arabinoside in the treatment of congenital cytomegalic inclusion disease | |
| Schutte et al. | The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour | |
| KR20250040723A (ko) | 박출율 보존 심부전의 치료를 위한 의약의 제조에서 Jun 억제제의 용도 | |
| Morrow et al. | MS patients report excellent compliance with oral prednisone for acute relapses | |
| Kaplan et al. | Juvenile acute intermittent porphyria with hypercholesterolemia and epilepsy: a case report and review of the literature | |
| Cameron et al. | Herpes simplex virus encephalitis: problems in diagnosis | |
| MD967Z (ru) | Метод лечения хронического вирусного гепатита В с холестатическим синдромом у детей | |
| Gardner et al. | Androstane therapy to treat aplastic anaemia in adults: an uncontrolled pilot study | |
| Koren et al. | Fetal pharmacotherapy | |
| Stavinoha et al. | Current therapy of chronic liver disease | |
| De Bittencourt et al. | Multiple sclerosis: long‐term remission after a high dose of cyclophosphamide | |
| CN107260750A (zh) | 人参皂苷Rb1在制备治疗免疫性复发性流产药物中的用途及其药物组合物 | |
| Martin | Non-otogenic cerebral abscess | |
| MD596Z (ru) | Метод лечения хронического вирусного гепатита С у детей | |
| Venkataramaiah et al. | Management of myasthenia gravis | |
| CN107468742B (zh) | 一种雷公藤多苷及雷公藤红素单体增效减毒配伍方法 | |
| Owhonda et al. | Parenteral Hydrocortisone treatment in a COVID-19 patient with Respiration Distress–a case report | |
| GC et al. | Parenteral Hydrocortisone treatment in a COVID-19 patient with Respiration Distress–a case report | |
| CN110882286A (zh) | 去壁灵芝孢子粉的用途 | |
| CN104284670B (zh) | 用于治疗丙型病毒性肝炎的药剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| MK4Y | Short term patent expired |